Patents by Inventor Francois Bourdon
Francois Bourdon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959313Abstract: A latch assembly for an access door of a storage compartment in a vehicle, includes a locking bar configured to move into an engaged configuration which enables the access door to be placed and held into a closed position and a disengaged configuration which permits the access door to be placed into an opened position; and an automatic locking mechanism including a shape memory alloy (SMA) actuator configured to be coupled to the access door, and further including a locking feature operably coupled to a portion of the locking bar, and configured to engage and disengage the SMA actuator which is electrically energized to move into a locked position to prohibit the locking feature from moving. A latch assembly for an access door of a storage compartment in a vehicle includes an SMA actuator configured to move the locking bar into the disengaged configuration with the storage compartment.Type: GrantFiled: December 2, 2019Date of Patent: April 16, 2024Assignee: Motherson Innovations Company LimitedInventors: Romeo Wieczorek, David-Kenneth Jaeger, Jean-Francois Bourdon, Ludovic Carpentier
-
Publication number: 20230383016Abstract: The invention has for object a method of selecting a composition comprising crosslinked hyaluronic acid (HA) and a low proportion of soluble hyaluronic acid for use in limiting the risk of appearance of an adverse side effect associated with the administration of a composition comprising crosslinked HA.Type: ApplicationFiled: October 11, 2021Publication date: November 30, 2023Applicant: TEOXANE SAInventors: Jimmy FAIVRE, François BOURDON
-
Publication number: 20230157941Abstract: A hyaluronic acid-based aqueous gel including crosslinked hyaluronic acid and from 30 to 70% by mass with respect to the total mass of hyaluronic acid, of a water-soluble hyaluronic acid. A method for preparing an aqueous gel having at least a crosslinked hyaluronic acid and at least an uncrosslinked hyaluronic acid. Also an aqueous gel obtainable by the method compositions, a cosmetic and/or dermatological composition including the aqueous gels, and a kit comprising a pre-filled syringe comprising the aqueous gel or said composition. These gels and compositions are useful in particular for treating an alteration in the surface appearance of the skin and/or for augmenting and/or filling soft tissue.Type: ApplicationFiled: April 12, 2021Publication date: May 25, 2023Inventor: François BOURDON
-
Publication number: 20220362439Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: ApplicationFiled: July 12, 2022Publication date: November 17, 2022Inventors: Francois Bourdon, Stephane Meunier
-
Patent number: 11406738Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: GrantFiled: August 26, 2020Date of Patent: August 9, 2022Assignee: TEOXANEInventors: Francois Bourdon, Stephane Meunier
-
Publication number: 20220003024Abstract: A latch assembly 1 for an access door 2 of a storage compartment 3 in a vehicle 4, comprises a locking bar 5 configured to be movable into an engaged configuration which enables the access door 2 to be placed and held into a closed position and into a disengaged configuration which permits the access door 2 to be placed into an opened position; and an automatic locking mechanism 8 including a shape memory alloy (SMA) actuator 9 configured to be coupled to the access door 2, the automatic locking mechanism 8 further including a locking feature 10 operably coupled to at least a portion of the locking bar 5, 5?, and configured to engage and disengage the SMA actuator which is electrically energized to move into a locked position to prohibit the locking feature 10 from moving.Type: ApplicationFiled: December 2, 2019Publication date: January 6, 2022Inventors: Romeo Wieczorek, David-Kenneth Jaeger, Jean-Francois Bourdon, Ludovic Carpentier
-
Publication number: 20200390940Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: ApplicationFiled: August 26, 2020Publication date: December 17, 2020Inventors: Francois Bourdon, Stephane Meunier
-
Patent number: 10786601Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: GrantFiled: July 17, 2018Date of Patent: September 29, 2020Assignee: TEOXANEInventors: Francois Bourdon, Stephane Meunier
-
Patent number: 10740497Abstract: A method is disclosed for providing first data and a first secret key to a cipher processor for ciphering. The first data is ciphered in accordance with a first cipher process and the first secret key to provide output data. Before ciphering of the first data, extra data is inserted within the cipher processor for ciphering in accordance with at least a portion of said first cipher process. The extra data is inserted within a sequence of cipher processor operations for obfuscating the output data.Type: GrantFiled: June 1, 2018Date of Patent: August 11, 2020Assignee: Synopsys, Inc.Inventors: Neil Hamilton, Francois Bourdon, Michael Borza
-
Patent number: 10413637Abstract: A sterile composition for intraepidermal, intradermal, and/or subcutaneous administration including an effective amount of hyaluronic acid or a salt thereof, the effective amount of hyaluronic acid or salt thereof ranging from 1 to 3 wt % of the overall weight of the sterile composition, mepivacaine or a salt thereof as a first anesthetic agent at a concentration ranging from 0.05 to 3 wt % of an overall weight of the sterile composition, and a balanced salt solution in which the sterile composition exhibits greater stability over time and/or during heat treatment resulting in sterilization in comparison to the same composition having lidocaine as the anesthetic agent instead of mepivacaine.Type: GrantFiled: February 22, 2019Date of Patent: September 17, 2019Assignee: TEOXANEInventors: Francois Bourdon, Stephane Meunier
-
Publication number: 20190184065Abstract: A sterile composition for intraepidermal, intradermal, and/or subcutaneous administration including an effective amount of hyaluronic acid or a salt thereof, the effective amount of hyaluronic acid or salt thereof ranging from 1 to 3 wt % of the overall weight of the sterile composition, mepivacaine or a salt thereof as a first anesthetic agent at a concentration ranging from 0.05 to 3 wt % of an overall weight of the sterile composition, and a balanced salt solution in which the sterile composition exhibits greater stability over time and/or during heat treatment resulting in sterilization in comparison to the same composition having lidocaine as the anesthetic agent instead of mepivacaine.Type: ApplicationFiled: February 22, 2019Publication date: June 20, 2019Inventors: FRANCOIS BOURDON, Stephane Meunier
-
Patent number: 10322212Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: GrantFiled: February 13, 2018Date of Patent: June 18, 2019Assignee: TEOXANEInventors: Francois Bourdon, Stephane Meunier
-
Patent number: 10307512Abstract: The present invention relates to a process for preparing a crosslinked gel of at least one polysaccharide or a salt thereof, comprising at least the steps consisting in: a) providing a solution formed from an aqueous medium comprising at least said polysaccharide(s) or a salt thereof in a non-crosslinked form, at least one difunctional or multifunctional epoxide crosslinking agent chosen from butanediol diglycidyl ether, diepoxyoctane, 1,2-bis(2,3-epoxypropyl)-2,3-ethylene, and mixtures thereof, and at least one phosphate salt; b) crosslinking the solution from step a) and, where appropriate; c) recovering said crosslinked gel formed.Type: GrantFiled: December 15, 2015Date of Patent: June 4, 2019Assignee: TEOXANEInventors: Francois Bourdon, Stephane Meunier
-
Patent number: 10307362Abstract: The present invention relates to a crosslinked hyaluronic acid gel which derives from the crosslinking of hyaluronic acid or of a salt thereof in the presence of at least an effective amount of at least one endogenous polyamine as a crosslinking agent, said crosslinking being carried out under conditions favorable to the coupling of said hyaluronic acid and of said endogenous polyamine(s).Type: GrantFiled: January 18, 2018Date of Patent: June 4, 2019Assignee: TEOXANE SAInventors: François Bourdon, Stéphane Meunier
-
Patent number: 10132734Abstract: Process for evaluating the mechanical performance of a filler gel, comprising the step consisting in subjecting a sample of this gel to oscillating mechanical stresses making it possible to determine the elastic modulus G? and to deliver a score representative of the integration of G? over the stress and/or the deformation strain within a stress and/or strain interval that includes values of the modulus G? encountered beyond the linear viscoelasticity plateau.Type: GrantFiled: March 22, 2016Date of Patent: November 20, 2018Assignee: TEOXANEInventors: Francois Bourdon, Stephane Meunier
-
Publication number: 20180318469Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: ApplicationFiled: July 17, 2018Publication date: November 8, 2018Inventors: Francois Bourdon, Stephane Meunier
-
Patent number: 10103876Abstract: A processor is disclosed for ciphering of first data. The processor includes a key store and a first data store. In use the processor for ciphering the first data in accordance with a first cipher process and a first secret key to provide output data, during ciphering of the first data inserting within the cipher processor other data for ciphering in accordance with at least a portion of the first cipher process, the other data inserted within a sequence of cipher processor operations and scheduled for obfuscating the output data.Type: GrantFiled: October 17, 2013Date of Patent: October 16, 2018Assignee: Synopsys, Inc.Inventors: Neil Hamilton, François Bourdon, Michael Borza
-
Publication number: 20180278411Abstract: A method is disclosed for providing first data and a first secret key to a cipher processor for ciphering. The first data is ciphered in accordance with a first cipher process and the first secret key to provide output data. Before ciphering of the first data, extra data is inserted within the cipher processor for ciphering in accordance with at least a portion of said first cipher process. The extra data is inserted within a sequence of cipher processor operations for obfuscating the output data.Type: ApplicationFiled: June 1, 2018Publication date: September 27, 2018Inventors: Neil Hamilton, Francois Bourdon, Michael Borza
-
Publication number: 20180169304Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: ApplicationFiled: February 13, 2018Publication date: June 21, 2018Inventors: FRANCOIS BOURDON, Stephane Meunier
-
Publication number: 20180140530Abstract: The present invention relates to a crosslinked hyaluronic acid gel which derives from the crosslinking of hyaluronic acid or of a salt thereof in the presence of at least an effective amount of at least one endogenous polyamine as a crosslinking agent, said crosslinking being carried out under conditions favourable to the coupling of said hyaluronic acid and of said endogenous polyamine(s).Type: ApplicationFiled: January 18, 2018Publication date: May 24, 2018Inventors: Francois BOURDON, Stéphane Meunier